Literature DB >> 14673982

Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade.

Kurt Redlich1, Georg Schett, Günter Steiner, Silvia Hayer, Erwin F Wagner, Josef S Smolen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14673982     DOI： 10.1002/art.11358

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  20 in total

Review 1.  Osteoclastogenesis and arthritis.

Authors:  Nicola Maruotti; Maria Grano; Silvia Colucci; Francesca d'Onofrio; Francesco Paolo Cantatore
Journal:  Clin Exp Med       Date:  2010-11-11       Impact factor: 3.984

Review 2.  Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis.

Authors:  Alice Capogrosso Sansone; Stefania Mantarro; Marco Tuccori; Elisa Ruggiero; Sabrina Montagnani; Irma Convertino; Alessandra Marino; Matteo Fornai; Luca Antonioli; Tiberio Corona; Danila Garibaldi; Corrado Blandizzi
Journal:  Drug Saf       Date:  2015-10       Impact factor: 5.606

3.  Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis.

Authors:  Anthony Russell; Ariel Beresniak; Louis Bessette; Boulos Haraoui; Proton Rahman; Carter Thorne; Ross Maclean; Danielle Dupont
Journal:  Clin Rheumatol       Date:  2008-12-17       Impact factor: 2.980

4.  Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis.

Authors:  M Vigna-Pérez; C Abud-Mendoza; H Portillo-Salazar; B Alvarado-Sánchez; E Cuevas-Orta; R Moreno-Valdés; L Baranda; O Paredes-Saharopulos; R González-Amaro
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

Review 5.  To switch or to change class-the biologic dilemma in rheumatoid arthritis.

Authors:  Edith Villeneuve; Boulos Haraoui
Journal:  Nat Rev Rheumatol       Date:  2010-04-13       Impact factor: 20.543

6.  Effects of 18β-Glycyrrhetinic acid in hTNFtg mice - a model of rheumatoid arthritis.

Authors:  Antonia Puchner; Silvia Hayer; Birgit Niederreiter; Anastasiya Hladik; Stephan Blueml; Michael Bonelli; Clemens Scheinecker; Josef Smolen; Kurt Redlich
Journal:  Wien Klin Wochenschr       Date:  2012-01-03       Impact factor: 1.704

7.  Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.

Authors:  A Finckh; J F Simard; C Gabay; P-A Guerne
Journal:  Ann Rheum Dis       Date:  2005-12-08       Impact factor: 19.103

8.  A proposal of simple calculation (ERI calculator) to predict the early response to TNF-α blockers therapy in rheumatoid arthritis.

Authors:  Laura Bazzichi; Paolo Rossi; Camillo Giacomelli; Francesca De Feo; Francesca Bobbio-Pallavicini; Alessandra Rossi; Chiara Baldini; Arianna Consensi; Marica Doveri; Claudia Bonino; Maurizio Mazzantini; Alessandra Della Rossa; Carlomaurizio Montecucco; Stefano Bombardieri
Journal:  Rheumatol Int       Date:  2010-11-26       Impact factor: 2.631

9.  Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial.

Authors:  J Smolen; R B Landewé; P Mease; J Brzezicki; D Mason; K Luijtens; R F van Vollenhoven; A Kavanaugh; M Schiff; G R Burmester; V Strand; J Vencovsky; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2008-11-17       Impact factor: 19.103

10.  Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

Authors:  A Finckh; A Ciurea; L Brulhart; B Möller; U A Walker; D Courvoisier; D Kyburz; J Dudler; C Gabay
Journal:  Ann Rheum Dis       Date:  2009-05-04       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.